Please use this identifier to cite or link to this item:
Title: Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response.
Authors: Herrero-Fernández, Inés
Pacheco, Yolanda M
Genebat, Miguel
Rodriguez-Méndez, María Del Mar
Lozano, María Del Carmen
Polaino, María José
Rosado-Sánchez, Isaac
Tarancón-Diez, Laura
Muñoz-Fernández, María Ángeles
Ruiz-Mateos, Ezequiel
Leal, Manuel
Keywords: HIV infection;combined antiretroviral treatment;hepatitis A virus;hepatitis B virus;maraviroc;vaccine
metadata.dc.subject.mesh: Adult
Anti-Retroviral Agents
Hepatitis B
Hepatitis B Antibodies
Hepatitis B Vaccines
Hepatitis B virus
Immunization, Secondary
Middle Aged
Issue Date: 21-Dec-2017
Abstract: The response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine. Fifty-seven patients on suppressor cART were administered the HBV vaccine. The final response, the early response, and the maintenance of the response were assessed. An anti-HBs titer of >10 mIU/ml was considered a positive response. A subgroup of subjects was simultaneously vaccinated against hepatitis A virus (HAV). Lineal regression analyses were performed to determine demographic, clinical, and immunological factors associated with the anti-HBs titer. Vaccine response was achieved in 90% of the subjects. After 1 year, 81% maintained protective titers. Only simultaneous HAV vaccination was independently associated with the magnitude of the response in anti-HBs titers, with a P value of 0.045 and a regression coefficient (B) [95% confident interval (CI)] of 236 [5 to 468]. In subjects ≤50 years old (n = 42), MVC-cART was independently associated with the magnitude of the response (P = 0.009; B [95% CI], 297 [79 to 516]) together with previous vaccination and simultaneous HAV vaccination. High rates of HBV vaccine response can be achieved by revaccination, simultaneous HAV vaccination, and administration of cARTs including MVC. MVC may be considered for future vaccination protocols in patients on suppressive cART.
metadata.dc.identifier.doi: 10.1128/AAC.02050-17
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.